Q-omics provides the consensus-scored SNORD116-25 profile across patient tissues and cancer cell-line models. SNORD116-25 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SNORD116-25 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, SNORD116-25 RNA expression shows 10,325 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight LIHC, THCA, and SARC as cancer lineages where SNORD116-25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD116-25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD116-25 survival associations across molecular data types. SNORD116-25 RNA expression shows survival associations in the most cancer types (7), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD116-25 RNA expression–survival associations across cancer types. High SNORD116-25 expression shows unfavorable associations in LIHC, BRCA, THCA, STAD and LUAD, but favorable associations in TGCT. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for SNORD116-25 RNA expression.
This table summarizes SNORD116-25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD116-25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD116-25 shows lower tumor expression in THCA and higher tumor expression in LUAD. The THCA box plot shows higher SNORD116-25 RNA expression in normal versus tumor tissue (log2 FC = −0.215, t-test p = .011).
This table shows molecular features associated with SNORD116-25 in patient tissues and cancer cell lines. In patient samples, SNORD116-25 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
